Krystal Biotech Inc (KRYS)
Return on total capital
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 12,897 | -139,975 | -68,078 | -32,167 | -22,081 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 778,641 | 522,231 | 593,576 | 292,084 | 202,914 |
| Return on total capital | 1.66% | -26.80% | -11.47% | -11.01% | -10.88% |
December 31, 2023 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $12,897K ÷ ($—K + $778,641K)
= 1.66%
Krystal Biotech Inc's return on total capital exhibited a significant improvement in 2023, reaching 1.66% from negative figures in the previous years. The negative returns in 2020 to 2022 indicated that the company was not effectively generating returns on the total capital employed during those years. However, the positive return in 2023 suggests a better ability to utilize its total capital to generate profits. Further analysis of the company's financial performance and operational efficiency would be necessary to determine the factors driving this improvement and sustainability of the positive trend.
Peer comparison
Dec 31, 2023